This article was originally published in The Gray Sheet
Executive SummaryBob Guezuraga is named senior-VP and president of the company's Cardiac Surgery business effective Sept. 1, Medtronic reports Aug. 13. Guezuraga currently serves as VP and general manager of Medtronic's Physio-Control division. Jodi Harpstead is adding global marketing for the firm's Cardiac Rhythm Management division to her current responsibilities as head of U.S. sales and marketing for that business. Taking over as VP-U.S. sales and marketing for the Cardiac Surgery unit is 23-year Medtronic veteran Dan Pelak. The newly created position of VP-corporate marketing will be held by Chuck Brynelsen, who currently serves as VP-U.S. CRM marketing
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.